Schwab Charles Investment Management Inc. raised its holdings in Repligen Co. (NASDAQ:RGEN) by 6.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 202,201 shares of the biotechnology company’s stock after acquiring an additional 11,784 shares during the period. Schwab Charles Investment Management Inc. owned about 0.46% of Repligen worth $9,512,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in RGEN. Fred Alger Management Inc. grew its position in Repligen by 96.3% in the second quarter. Fred Alger Management Inc. now owns 740,574 shares of the biotechnology company’s stock valued at $34,837,000 after acquiring an additional 363,339 shares during the last quarter. OppenheimerFunds Inc. grew its position in Repligen by 18.5% in the first quarter. OppenheimerFunds Inc. now owns 1,989,639 shares of the biotechnology company’s stock valued at $71,985,000 after acquiring an additional 310,164 shares during the last quarter. Jennison Associates LLC grew its position in Repligen by 753.1% in the second quarter. Jennison Associates LLC now owns 206,804 shares of the biotechnology company’s stock valued at $9,728,000 after acquiring an additional 182,562 shares during the last quarter. Conestoga Capital Advisors LLC grew its position in Repligen by 6.7% in the second quarter. Conestoga Capital Advisors LLC now owns 1,711,132 shares of the biotechnology company’s stock valued at $80,492,000 after acquiring an additional 107,095 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Repligen by 10.8% in the first quarter. Dimensional Fund Advisors LP now owns 1,013,331 shares of the biotechnology company’s stock valued at $36,662,000 after acquiring an additional 98,864 shares during the last quarter. Hedge funds and other institutional investors own 92.50% of the company’s stock.

Shares of RGEN stock opened at $55.07 on Tuesday. Repligen Co. has a 12 month low of $29.56 and a 12 month high of $58.99. The stock has a market cap of $2.42 billion, a PE ratio of 81.24, a PEG ratio of 4.45 and a beta of 0.72.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported $0.16 EPS for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.02). Repligen had a net margin of 13.49% and a return on equity of 5.05%. The firm had revenue of $47.73 million for the quarter, compared to analyst estimates of $45.84 million. During the same period in the previous year, the business posted $0.20 earnings per share. The business’s revenue for the quarter was up 47.0% compared to the same quarter last year. sell-side analysts anticipate that Repligen Co. will post 0.71 EPS for the current fiscal year.

RGEN has been the topic of a number of recent research reports. Stephens lifted their price target on Repligen from $50.00 to $55.00 and gave the company an “average” rating in a research note on Tuesday, July 10th. BidaskClub lowered Repligen from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 31st. Citigroup lifted their price target on Repligen from $45.00 to $56.00 and gave the company a “buy” rating in a research note on Friday, July 20th. ValuEngine raised Repligen from a “hold” rating to a “buy” rating in a research note on Thursday, June 28th. Finally, JPMorgan Chase & Co. lifted their price target on Repligen to $60.00 and gave the company an “overweight” rating in a research note on Monday. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. Repligen has a consensus rating of “Buy” and a consensus price target of $49.43.

In related news, CEO Anthony Hunt sold 27,566 shares of Repligen stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $57.71, for a total value of $1,590,833.86. Following the transaction, the chief executive officer now directly owns 255,017 shares of the company’s stock, valued at $14,717,031.07. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Roy T. Eddleman sold 4,770 shares of Repligen stock in a transaction that occurred on Wednesday, August 8th. The stock was sold at an average price of $49.05, for a total value of $233,968.50. Following the completion of the transaction, the insider now directly owns 413,985 shares in the company, valued at $20,305,964.25. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 88,884 shares of company stock worth $4,693,683. 1.40% of the stock is owned by insiders.

Repligen Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Featured Article: Index Funds

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.